The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
A new column on the uninsured from President and CEO Dr. Drew Altman explains: “The uninsured is not the most politically salient problem in health care now, that’s affordability, nor is it the non-problem some say it is. But it’s coming back. And the problem of the chronically ill uninsured is glaring.” Read more.
In his latest column, President and CEO Dr. Drew Altman asks if prior authorization review could be eliminated entirely, discussing how it might be done and the tradeoffs.
Opioid overdose deaths fell sharply from 2023 to 2024 (79,358 to 54,045), driven largely by decreases in fentanyl-involved deaths. Even after these declines, deaths remained above 2019, the year before opioid deaths increased sharply during the pandemic.
Suicide deaths fell slightly from their peak of 49,476 deaths in 2022 to 48,824 deaths in 2024, but trends by suicide method diverged: suicides by other means declined while firearm suicides reached their highest level and accounted for 57% of all suicides (up from 50% in 2014).
Due to a combination of lower coverage rates, additional access barriers, and historical and ongoing discrimination, AIAN people continue to face significant disparities in health and health care.
This analysis examines the share of noncitizen and citizen adults currently living in the U.S. who have one of the health conditions identified in new State Department guidance for visa screening.
About one in eight adults say that they are currently taking a GLP-1 drug either to lose weight or treat a chronic condition, an increase from 18 months ago, though the high costs of the medications remain a concern. Few adults think it is likely their prescription costs will go down as a result of recently announced Trump administration policies.
About one in eight adults (12%) say that they are currently taking a GLP-1 drug such as Ozempic or Wegovy either to lose weight or treat a chronic condition, an increase from 18 months ago, though the high costs of the medications remain a concern, a new KFF Health Tracking Poll finds. Overall nearly one in five adults (18%) say at some point they have taken a GLP-1 drug, a class of medications used for…
KFF and ESPN today jointly released a first-of-its-kind, in-depth polling and reporting project that sheds new light on the health issues and other challenges facing NFL players after they leave the game. The KFF/ESPN Survey of 1988 NFL Players draws on a novel survey of 546 respondents who were among the 1,532 players from the 1988 season. Now, at an average age of 62, large majorities of these former NFL players say pro football was bad…
© 2026 KFF
